An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor-Reference-Cited by-同舟云学术

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor

Published:2017-11 Issue:11 Volume:14 Page:1662-1666
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Jennings Mark T.¹^ORCID,Dezube Rebecca¹,Paranjape Shruti²,West Natalie E.¹,Hong Gina³,Braun Andrew¹,Grant Jonathan⁴,Merlo Christian A.¹,Lechtzin Noah¹

Affiliation:

1. Department of Medicine, Division of Pulmonary and Critical Care Medicine

2. Department of Pediatrics, Division of Pulmonary Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

3. Department of Medicine, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania; and

4. Johns Hopkins Medicine, Pharmacy, Baltimore, Maryland

Publisher

American Thoracic Society

Subject

Pulmonary and Respiratory Medicine

Link

http://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201701-058OC

Reference11 articles.

1. Adult Cystic Fibrosis

2. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator

3. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

4. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

5. Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous forF508del-CFTR

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle-based platforms for targeted drug delivery to the pulmonary system as therapeutics to curb cystic fibrosis: A review;Journal of Microbiological Methods;2024-02

2. HPLC method for simultaneous quantification of lumacaftor and ivacaftor bulk and pharmaceutical formulations;European Journal of Life Sciences;2023-12-29

3. The gut-lung axis in the CFTR modulator era;Frontiers in Cellular and Infection Microbiology;2023-09-15

4. Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators;International Journal of Molecular Sciences;2023-08-29

5. Validation of secretory Immunoglobulin A (IgA) for early and efficient diagnosis of Pseudomonas aeruginosa lung infection;Cellular and Molecular Biology;2023-07-31